Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for Erbb2-Positive Locally Recurrent or Metastatic Breast Cancer

    Summary
    EudraCT number
    2008-007803-10
    Trial protocol
    HU   DE   IT   GB   ES   BE   LV   PT   LT   FR   GR   DK   MT   BG  
    Global end of trial date
    28 Jun 2018

    Results information
    Results version number
    v1(current)
    This version publication date
    14 Jul 2019
    First version publication date
    14 Jul 2019
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    3144A2-3005
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT00915018
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Puma Biotechnology, Inc.
    Sponsor organisation address
    10880 Wilshire Blvd, Suite 2150, Los Angeles, United States, 90024
    Public contact
    Senior Director, Clinical Operations, Puma Biotechnology, Inc., 4242486500 4242486500, clinicaltrials@pumabiotechnology.com
    Scientific contact
    Senior Director, Clinical Operations, Puma Biotechnology, Inc., 1 4242486500, clinicaltrials@pumabiotechnology.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    28 Jun 2018
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    28 Jun 2018
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To compare the independently assessed progression-free survival following treatment with neratinib in combination with paclitaxel versus trastuzumab plus paclitaxel in subjects who have not received previous treatment for erbB-2-positive locally recurrent or metastatic breast cancer.
    Protection of trial subjects
    This study was conducted in accordance with the ethical principles of the International Conference for Harmonisation (ICH), guideline for Good Clinical Practice (GCP), including the Declaration of Helsinki and the applicable laws and regulations. The PI or designee promptly submitted the protocol to the applicable IRB/EC, and obtained approval to begin study-related activities. All participants provided informed consent prior to the performance of any protocol procedures and before administration of investigational product.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    21 Aug 2009
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Australia: 1
    Country: Number of subjects enrolled
    Belgium: 4
    Country: Number of subjects enrolled
    Bulgaria: 1
    Country: Number of subjects enrolled
    Belarus: 6
    Country: Number of subjects enrolled
    Canada: 3
    Country: Number of subjects enrolled
    Switzerland: 4
    Country: Number of subjects enrolled
    China: 41
    Country: Number of subjects enrolled
    Germany: 1
    Country: Number of subjects enrolled
    Spain: 23
    Country: Number of subjects enrolled
    France: 16
    Country: Number of subjects enrolled
    United Kingdom: 3
    Country: Number of subjects enrolled
    Hong Kong: 7
    Country: Number of subjects enrolled
    Croatia: 4
    Country: Number of subjects enrolled
    Hungary: 9
    Country: Number of subjects enrolled
    India: 57
    Country: Number of subjects enrolled
    Israel: 7
    Country: Number of subjects enrolled
    Italy: 5
    Country: Number of subjects enrolled
    Japan: 81
    Country: Number of subjects enrolled
    Korea, Republic of: 16
    Country: Number of subjects enrolled
    Lithuania: 7
    Country: Number of subjects enrolled
    Latvia: 5
    Country: Number of subjects enrolled
    Malta: 3
    Country: Number of subjects enrolled
    Malaysia: 5
    Country: Number of subjects enrolled
    Poland: 10
    Country: Number of subjects enrolled
    Portugal: 2
    Country: Number of subjects enrolled
    Romania: 4
    Country: Number of subjects enrolled
    Singapore: 15
    Country: Number of subjects enrolled
    Serbia: 8
    Country: Number of subjects enrolled
    Taiwan: 2
    Country: Number of subjects enrolled
    Ukraine: 54
    Country: Number of subjects enrolled
    United States: 37
    Country: Number of subjects enrolled
    South Africa: 34
    Country: Number of subjects enrolled
    Bahamas: 4
    Worldwide total number of subjects
    479
    EEA total number of subjects
    97
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    392
    From 65 to 84 years
    87
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    -

    Pre-assignment
    Screening details
    Participants had to meet all inclusion criteria and not meet any exclusion criteria to participate in this study. A signed and dated informed consent was required before any screen procedures were done.

    Period 1
    Period 1 title
    Treatment Period (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Neratinib + Paclitaxel
    Arm description
    Paclitaxel in combination with neratinib (arm A: experimental arm) until objective disease progression, symptomatic deterioration, intolerable toxicity, death, or withdrawal of consent.
    Arm type
    Experimental

    Investigational medicinal product name
    Paclitaxel
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Paclitaxel will be administered IV (80 mg/m2) on days 1, 8, and 15 of a 28-day cycle. Subjects will receive paclitaxel treatment for at least 6 cycles. Additional cycles can be given at the investigator’s discretion. Treatment will be stopped in case of disease progression, symptomatic deterioration, unacceptable toxicity, death, or withdrawal of consent occurs.

    Investigational medicinal product name
    Neratinib
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    The number of neratinib tablets taken will depend on the prescribed dose. Neratinib (240 mg initial dose, provided as 40 mg tablets) will be taken on a daily basis, starting with day 1, by mouth with food, preferably in the morning until disease progression, symptomatic deterioration, unacceptable toxicity, death, or withdrawal of consent occurs.

    Arm title
    Trastuzumab + Paclitaxel
    Arm description
    Paclitaxel in combination with trastuzumab (arm B: control arm) until objective disease progression, symptomatic deterioration, intolerable toxicity, death, or withdrawal of consent.
    Arm type
    Active comparator

    Investigational medicinal product name
    Trastuzumab
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Trastuzumab will be administered at an initial loading dose of 4 mg/kg as an approximately 90 minutes IV infusion followed by subsequent once weekly doses of 2 mg/kg as 30-90 minute IV infusions until disease progression, symptomatic deterioration, unacceptable toxicity, death, or withdrawal of consent occurs.

    Investigational medicinal product name
    Paclitaxel
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Paclitaxel will be administered IV (80 mg/m2) on days 1, 8, and 15 of a 28-day cycle. Subjects will receive paclitaxel treatment for at least 6 cycles. Additional cycles can be given at the investigator’s discretion. Treatment will be stopped in case of disease progression, symptomatic deterioration, unacceptable toxicity, death, or withdrawal of consent occurs.

    Number of subjects in period 1
    Neratinib + Paclitaxel Trastuzumab + Paclitaxel
    Started
    242
    237
    Completed
    0
    0
    Not completed
    242
    237
         Consent withdrawn by subject
    41
    37
         Physician decision
    -
    1
         Disease progression
    4
    -
         Death
    76
    70
         Screen failure
    -
    2
         Discontinuation of study by sponsor
    111
    122
         Lost to follow-up
    10
    5

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Neratinib + Paclitaxel
    Reporting group description
    Paclitaxel in combination with neratinib (arm A: experimental arm) until objective disease progression, symptomatic deterioration, intolerable toxicity, death, or withdrawal of consent.

    Reporting group title
    Trastuzumab + Paclitaxel
    Reporting group description
    Paclitaxel in combination with trastuzumab (arm B: control arm) until objective disease progression, symptomatic deterioration, intolerable toxicity, death, or withdrawal of consent.

    Reporting group values
    Neratinib + Paclitaxel Trastuzumab + Paclitaxel Total
    Number of subjects
    242 237 479
    Age categorical
    Units: Subjects
        Adults (18-64 years)
    199 193 392
        From 65-84 years
    43 44 87
        85 years and over
    0 0 0
    Gender categorical
    Units: Subjects
        Female
    242 237 479
        Male
    0 0 0

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Neratinib + Paclitaxel
    Reporting group description
    Paclitaxel in combination with neratinib (arm A: experimental arm) until objective disease progression, symptomatic deterioration, intolerable toxicity, death, or withdrawal of consent.

    Reporting group title
    Trastuzumab + Paclitaxel
    Reporting group description
    Paclitaxel in combination with trastuzumab (arm B: control arm) until objective disease progression, symptomatic deterioration, intolerable toxicity, death, or withdrawal of consent.

    Primary: Progression-Free Survival

    Close Top of page
    End point title
    Progression-Free Survival
    End point description
    The primary endpoint was PFS, defined as the interval from the date of randomization until the first date on which recurrence or progression, or death due to any cause, was documented, censored at the last assessable evaluation or at the initiation of new anticancer therapy.
    End point type
    Primary
    End point timeframe
    From randomization date through recurrence, progression, or death due to any cause.
    End point values
    Neratinib + Paclitaxel Trastuzumab + Paclitaxel
    Number of subjects analysed
    242
    237
    Units: Months
        median (confidence interval 95%)
    12.9 (11.1 to 14.9)
    12.9 (11.1 to 14.8)
    Statistical analysis title
    PFS
    Comparison groups
    Neratinib + Paclitaxel v Trastuzumab + Paclitaxel
    Number of subjects included in analysis
    479
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.8934 [1]
    Method
    Logrank
    Parameter type
    Hazard ratio (HR)
    Point estimate
    1.015
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.813
         upper limit
    1.269
    Notes
    [1] - Log-rank test and Cox model are stratified by randomization stratification factors: prior adjuvant trastuzumab exposure, prior lapatinib exposure, ER/PgR status (positive or negative), and region.

    Secondary: Objective Response Rate

    Close Top of page
    End point title
    Objective Response Rate
    End point description
    Objective response rate (ORR) was defined as the proportion of patients who achieved confirmed CR or PR, per RECIST (v1.0) criteria, as their best overall response. The best overall response was the best response recorded from randomization until disease progression/recurrence (taking as reference for progressive disease (PD) the smallest measurements recorded since randomization).
    End point type
    Secondary
    End point timeframe
    From date of randomization through last tumor assessment.
    End point values
    Neratinib + Paclitaxel Trastuzumab + Paclitaxel
    Number of subjects analysed
    242
    237
    Units: Percentage
        number (confidence interval 95%)
    74.8 (68.8 to 80.1)
    77.6 (71.8 to 82.8)
    No statistical analyses for this end point

    Secondary: Duration of Response

    Close Top of page
    End point title
    Duration of Response
    End point description
    For patients who had a confirmed response, the duration of response (DOR) was measured from the time at which measurement criteria were first met for confirmed CR or PR, until the date of first recurrence, PD, or death was objectively documented, taking as a reference for PD the smallest measurements recorded since enrollment.
    End point type
    Secondary
    End point timeframe
    From the time at which measurement criteria were first met for confirmed CR or PR, until the date of first recurrence, PD, or death was objectively documented, taking as a reference for PD the smallest measurements recorded since enrollment.
    End point values
    Neratinib + Paclitaxel Trastuzumab + Paclitaxel
    Number of subjects analysed
    181
    184
    Units: Months
        median (confidence interval 95%)
    13.1 (11.1 to 15.4)
    12.9 (11.0 to 15.1)
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    1st dose through 28 days after last dose
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    17.0
    Reporting groups
    Reporting group title
    Trastuzumab + Paclitaxel
    Reporting group description
    Paclitaxel in combination with trastuzumab (arm B: control arm) until objective disease progression, symptomatic deterioration, intolerable toxicity, death, or withdrawal of consent.

    Reporting group title
    Neratinib + Paclitaxel
    Reporting group description
    Paclitaxel in combination with neratinib (arm A: experimental arm) until objective disease progression, symptomatic deterioration, intolerable toxicity, death, or withdrawal of consent.

    Serious adverse events
    Trastuzumab + Paclitaxel Neratinib + Paclitaxel
    Total subjects affected by serious adverse events
         subjects affected / exposed
    57 / 234 (24.36%)
    67 / 240 (27.92%)
         number of deaths (all causes)
    72
    79
         number of deaths resulting from adverse events
    7
    8
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Benign ovarian tumour
         subjects affected / exposed
    0 / 234 (0.00%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cancer pain
         subjects affected / exposed
    1 / 234 (0.43%)
    0 / 240 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastric cancer
         subjects affected / exposed
    0 / 234 (0.00%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Metastases to central nervous system
         subjects affected / exposed
    5 / 234 (2.14%)
    2 / 240 (0.83%)
         occurrences causally related to treatment / all
    0 / 5
    0 / 2
         deaths causally related to treatment / all
    0 / 2
    0 / 1
    Metastases to meninges
         subjects affected / exposed
    1 / 234 (0.43%)
    0 / 240 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Ovarian epithelial cancer
         subjects affected / exposed
    1 / 234 (0.43%)
    0 / 240 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Ureteric cancer
         subjects affected / exposed
    1 / 234 (0.43%)
    0 / 240 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Vascular disorders
    Deep vein thrombosis
         subjects affected / exposed
    1 / 234 (0.43%)
    0 / 240 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hypertension
         subjects affected / exposed
    1 / 234 (0.43%)
    0 / 240 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hypotension
         subjects affected / exposed
    0 / 234 (0.00%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Shock
         subjects affected / exposed
    0 / 234 (0.00%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    1 / 1
    General disorders and administration site conditions
    Adhesion
         subjects affected / exposed
    0 / 234 (0.00%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Disease progression
         subjects affected / exposed
    0 / 234 (0.00%)
    3 / 240 (1.25%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 3
    Fatigue
         subjects affected / exposed
    1 / 234 (0.43%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    1 / 1
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Generalised oedema
         subjects affected / exposed
    0 / 234 (0.00%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Multi-organ failure
         subjects affected / exposed
    1 / 234 (0.43%)
    0 / 240 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Oedema peripheral
         subjects affected / exposed
    1 / 234 (0.43%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pyrexia
         subjects affected / exposed
    5 / 234 (2.14%)
    3 / 240 (1.25%)
         occurrences causally related to treatment / all
    2 / 7
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Sudden death
         subjects affected / exposed
    1 / 234 (0.43%)
    0 / 240 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Swelling
         subjects affected / exposed
    1 / 234 (0.43%)
    0 / 240 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Immune system disorders
    Contrast media allergy
         subjects affected / exposed
    1 / 234 (0.43%)
    0 / 240 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Drug hypersensitivity
         subjects affected / exposed
    1 / 234 (0.43%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    1 / 1
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Food allergy
         subjects affected / exposed
    0 / 234 (0.00%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Type IV hypersensitivity reaction
         subjects affected / exposed
    0 / 234 (0.00%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Reproductive system and breast disorders
    Menorrhagia
         subjects affected / exposed
    0 / 234 (0.00%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Uterine polyp
         subjects affected / exposed
    1 / 234 (0.43%)
    0 / 240 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Dyspnoea
         subjects affected / exposed
    2 / 234 (0.85%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    2 / 2
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pleural effusion
         subjects affected / exposed
    2 / 234 (0.85%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 4
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pneumonia aspiration
         subjects affected / exposed
    1 / 234 (0.43%)
    0 / 240 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pneumonitis
         subjects affected / exposed
    2 / 234 (0.85%)
    0 / 240 (0.00%)
         occurrences causally related to treatment / all
    2 / 2
    0 / 0
         deaths causally related to treatment / all
    1 / 1
    0 / 0
    Pneumothorax
         subjects affected / exposed
    0 / 234 (0.00%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pulmonary embolism
         subjects affected / exposed
    0 / 234 (0.00%)
    2 / 240 (0.83%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Respiratory failure
         subjects affected / exposed
    1 / 234 (0.43%)
    0 / 240 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 1
    0 / 0
    Psychiatric disorders
    Confusional state
         subjects affected / exposed
    0 / 234 (0.00%)
    4 / 240 (1.67%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Depression
         subjects affected / exposed
    1 / 234 (0.43%)
    0 / 240 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Schizophrenia
         subjects affected / exposed
    1 / 234 (0.43%)
    0 / 240 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Investigations
    Activated partial thromboplastin time prolonged
         subjects affected / exposed
    0 / 234 (0.00%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Alanine aminotransferase increased
         subjects affected / exposed
    1 / 234 (0.43%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 1
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Aspartate aminotransferase increased
         subjects affected / exposed
    1 / 234 (0.43%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    General physical condition abnormal
         subjects affected / exposed
    0 / 234 (0.00%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Weight decreased
         subjects affected / exposed
    0 / 234 (0.00%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Injury, poisoning and procedural complications
    Accidental overdose
         subjects affected / exposed
    3 / 234 (1.28%)
    2 / 240 (0.83%)
         occurrences causally related to treatment / all
    3 / 3
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Ankle fracture
         subjects affected / exposed
    0 / 234 (0.00%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Drug administration error
         subjects affected / exposed
    1 / 234 (0.43%)
    0 / 240 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Femur fracture
         subjects affected / exposed
    0 / 234 (0.00%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Intentional overdose
         subjects affected / exposed
    0 / 234 (0.00%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Ligament sprain
         subjects affected / exposed
    1 / 234 (0.43%)
    0 / 240 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Lower limb fracture
         subjects affected / exposed
    0 / 234 (0.00%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Overdose
         subjects affected / exposed
    0 / 234 (0.00%)
    2 / 240 (0.83%)
         occurrences causally related to treatment / all
    0 / 0
    4 / 5
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pneumothorax traumatic
         subjects affected / exposed
    1 / 234 (0.43%)
    0 / 240 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Procedural hypotension
         subjects affected / exposed
    0 / 234 (0.00%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cardiac disorders
    Atrial fibrillation
         subjects affected / exposed
    1 / 234 (0.43%)
    0 / 240 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cardiac failure congestive
         subjects affected / exposed
    0 / 234 (0.00%)
    2 / 240 (0.83%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cardiac tamponade
         subjects affected / exposed
    0 / 234 (0.00%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cardio-respiratory arrest
         subjects affected / exposed
    0 / 234 (0.00%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    1 / 1
    Left ventricular dysfunction
         subjects affected / exposed
    1 / 234 (0.43%)
    0 / 240 (0.00%)
         occurrences causally related to treatment / all
    2 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Myocardial infarction
         subjects affected / exposed
    0 / 234 (0.00%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pericardial effusion
         subjects affected / exposed
    0 / 234 (0.00%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Nervous system disorders
    Brain oedema
         subjects affected / exposed
    0 / 234 (0.00%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cerebellar ischaemia
         subjects affected / exposed
    1 / 234 (0.43%)
    0 / 240 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Coma
         subjects affected / exposed
    0 / 234 (0.00%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Headache
         subjects affected / exposed
    0 / 234 (0.00%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Spinal cord compression
         subjects affected / exposed
    1 / 234 (0.43%)
    0 / 240 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Transient ischaemic attack
         subjects affected / exposed
    0 / 234 (0.00%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    1 / 234 (0.43%)
    0 / 240 (0.00%)
         occurrences causally related to treatment / all
    3 / 3
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Febrile neutropenia
         subjects affected / exposed
    0 / 234 (0.00%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Leukopenia
         subjects affected / exposed
    0 / 234 (0.00%)
    2 / 240 (0.83%)
         occurrences causally related to treatment / all
    0 / 0
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Neutropenia
         subjects affected / exposed
    0 / 234 (0.00%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Thrombocytopenia
         subjects affected / exposed
    1 / 234 (0.43%)
    0 / 240 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Eye disorders
    Cataract
         subjects affected / exposed
    1 / 234 (0.43%)
    0 / 240 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Retinal degeneration
         subjects affected / exposed
    0 / 234 (0.00%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Uveitis
         subjects affected / exposed
    0 / 234 (0.00%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Abdominal pain
         subjects affected / exposed
    1 / 234 (0.43%)
    2 / 240 (0.83%)
         occurrences causally related to treatment / all
    0 / 1
    1 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Abdominal pain upper
         subjects affected / exposed
    0 / 234 (0.00%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Ascites
         subjects affected / exposed
    0 / 234 (0.00%)
    2 / 240 (0.83%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 3
         deaths causally related to treatment / all
    0 / 0
    1 / 1
    Dental caries
         subjects affected / exposed
    1 / 234 (0.43%)
    0 / 240 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Diarrhoea
         subjects affected / exposed
    3 / 234 (1.28%)
    12 / 240 (5.00%)
         occurrences causally related to treatment / all
    0 / 6
    17 / 17
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal haemorrhage
         subjects affected / exposed
    0 / 234 (0.00%)
    2 / 240 (0.83%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Ileus
         subjects affected / exposed
    1 / 234 (0.43%)
    0 / 240 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Intestinal obstruction
         subjects affected / exposed
    0 / 234 (0.00%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    1 / 1
    Nausea
         subjects affected / exposed
    1 / 234 (0.43%)
    2 / 240 (0.83%)
         occurrences causally related to treatment / all
    1 / 1
    3 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Rectal haemorrhage
         subjects affected / exposed
    0 / 234 (0.00%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Small intestinal obstruction
         subjects affected / exposed
    0 / 234 (0.00%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Volvulus
         subjects affected / exposed
    0 / 234 (0.00%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Vomiting
         subjects affected / exposed
    1 / 234 (0.43%)
    7 / 240 (2.92%)
         occurrences causally related to treatment / all
    0 / 1
    5 / 8
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hepatobiliary disorders
    Biliary colic
         subjects affected / exposed
    0 / 234 (0.00%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cholelithiasis
         subjects affected / exposed
    1 / 234 (0.43%)
    0 / 240 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hepatic failure
         subjects affected / exposed
    1 / 234 (0.43%)
    2 / 240 (0.83%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 1
    Hepatitis
         subjects affected / exposed
    1 / 234 (0.43%)
    0 / 240 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hyperbilirubinaemia
         subjects affected / exposed
    1 / 234 (0.43%)
    0 / 240 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Skin and subcutaneous tissue disorders
    Erythema
         subjects affected / exposed
    1 / 234 (0.43%)
    0 / 240 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Renal and urinary disorders
    Prerenal failure
         subjects affected / exposed
    0 / 234 (0.00%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Renal failure acute
         subjects affected / exposed
    0 / 234 (0.00%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Back pain
         subjects affected / exposed
    1 / 234 (0.43%)
    0 / 240 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Musculoskeletal chest pain
         subjects affected / exposed
    1 / 234 (0.43%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pain in extremity
         subjects affected / exposed
    1 / 234 (0.43%)
    0 / 240 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Rheumatoid arthritis
         subjects affected / exposed
    0 / 234 (0.00%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infections and infestations
    Appendicitis
         subjects affected / exposed
    1 / 234 (0.43%)
    0 / 240 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Candida infection
         subjects affected / exposed
    0 / 234 (0.00%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Catheter site cellulitis
         subjects affected / exposed
    1 / 234 (0.43%)
    0 / 240 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Cellulitis
         subjects affected / exposed
    6 / 234 (2.56%)
    0 / 240 (0.00%)
         occurrences causally related to treatment / all
    1 / 6
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Dengue fever
         subjects affected / exposed
    1 / 234 (0.43%)
    0 / 240 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Device related infection
         subjects affected / exposed
    2 / 234 (0.85%)
    2 / 240 (0.83%)
         occurrences causally related to treatment / all
    0 / 2
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Empyema
         subjects affected / exposed
    0 / 234 (0.00%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Furuncle
         subjects affected / exposed
    0 / 234 (0.00%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastroenteritis
         subjects affected / exposed
    0 / 234 (0.00%)
    3 / 240 (1.25%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Herpes zoster
         subjects affected / exposed
    1 / 234 (0.43%)
    0 / 240 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infection
         subjects affected / exposed
    0 / 234 (0.00%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Lower respiratory tract infection
         subjects affected / exposed
    1 / 234 (0.43%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 1
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pharyngitis
         subjects affected / exposed
    1 / 234 (0.43%)
    0 / 240 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pleural infection
         subjects affected / exposed
    1 / 234 (0.43%)
    0 / 240 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pneumonia
         subjects affected / exposed
    0 / 234 (0.00%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pulmonary tuberculosis
         subjects affected / exposed
    1 / 234 (0.43%)
    0 / 240 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Pyelonephritis acute
         subjects affected / exposed
    1 / 234 (0.43%)
    0 / 240 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Rash pustular
         subjects affected / exposed
    0 / 234 (0.00%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    4 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Respiratory tract infection
         subjects affected / exposed
    1 / 234 (0.43%)
    0 / 240 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Septic shock
         subjects affected / exposed
    0 / 234 (0.00%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    1 / 1
    Sinusitis
         subjects affected / exposed
    1 / 234 (0.43%)
    0 / 240 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Staphylococcal infection
         subjects affected / exposed
    0 / 234 (0.00%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Tooth abscess
         subjects affected / exposed
    1 / 234 (0.43%)
    0 / 240 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Upper respiratory tract infection
         subjects affected / exposed
    1 / 234 (0.43%)
    2 / 240 (0.83%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Urinary tract infection
         subjects affected / exposed
    1 / 234 (0.43%)
    0 / 240 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    Decreased appetite
         subjects affected / exposed
    2 / 234 (0.85%)
    1 / 240 (0.42%)
         occurrences causally related to treatment / all
    1 / 2
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Dehydration
         subjects affected / exposed
    1 / 234 (0.43%)
    7 / 240 (2.92%)
         occurrences causally related to treatment / all
    1 / 1
    7 / 8
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hyperglycaemia
         subjects affected / exposed
    1 / 234 (0.43%)
    0 / 240 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hypokalaemia
         subjects affected / exposed
    0 / 234 (0.00%)
    3 / 240 (1.25%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hyponatraemia
         subjects affected / exposed
    0 / 234 (0.00%)
    2 / 240 (0.83%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Trastuzumab + Paclitaxel Neratinib + Paclitaxel
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    230 / 234 (98.29%)
    239 / 240 (99.58%)
    Vascular disorders
    Hot flush
         subjects affected / exposed
    8 / 234 (3.42%)
    13 / 240 (5.42%)
         occurrences all number
    35
    34
    Hypertension
         subjects affected / exposed
    19 / 234 (8.12%)
    13 / 240 (5.42%)
         occurrences all number
    21
    26
    General disorders and administration site conditions
    Asthenia
         subjects affected / exposed
    36 / 234 (15.38%)
    53 / 240 (22.08%)
         occurrences all number
    67
    145
    Fatigue
         subjects affected / exposed
    64 / 234 (27.35%)
    78 / 240 (32.50%)
         occurrences all number
    295
    257
    Influenza like illness
         subjects affected / exposed
    14 / 234 (5.98%)
    10 / 240 (4.17%)
         occurrences all number
    76
    25
    Oedema
         subjects affected / exposed
    15 / 234 (6.41%)
    11 / 240 (4.58%)
         occurrences all number
    26
    17
    Oedema peripheral
         subjects affected / exposed
    40 / 234 (17.09%)
    34 / 240 (14.17%)
         occurrences all number
    67
    63
    Pain
         subjects affected / exposed
    13 / 234 (5.56%)
    13 / 240 (5.42%)
         occurrences all number
    18
    14
    Pyrexia
         subjects affected / exposed
    44 / 234 (18.80%)
    42 / 240 (17.50%)
         occurrences all number
    60
    64
    Reproductive system and breast disorders
    Breast pain
         subjects affected / exposed
    13 / 234 (5.56%)
    5 / 240 (2.08%)
         occurrences all number
    19
    6
    Respiratory, thoracic and mediastinal disorders
    Cough
         subjects affected / exposed
    47 / 234 (20.09%)
    24 / 240 (10.00%)
         occurrences all number
    77
    33
    Dyspnoea
         subjects affected / exposed
    22 / 234 (9.40%)
    28 / 240 (11.67%)
         occurrences all number
    29
    56
    Epistaxis
         subjects affected / exposed
    20 / 234 (8.55%)
    36 / 240 (15.00%)
         occurrences all number
    60
    225
    Oropharyngeal pain
         subjects affected / exposed
    20 / 234 (8.55%)
    20 / 240 (8.33%)
         occurrences all number
    28
    28
    Rhinorrhoea
         subjects affected / exposed
    17 / 234 (7.26%)
    6 / 240 (2.50%)
         occurrences all number
    26
    8
    Psychiatric disorders
    Insomnia
         subjects affected / exposed
    28 / 234 (11.97%)
    32 / 240 (13.33%)
         occurrences all number
    50
    64
    Investigations
    Alanine aminotransferase increased
         subjects affected / exposed
    26 / 234 (11.11%)
    31 / 240 (12.92%)
         occurrences all number
    70
    71
    Aspartate aminotransferase increased
         subjects affected / exposed
    22 / 234 (9.40%)
    26 / 240 (10.83%)
         occurrences all number
    46
    36
    Blood alkaline phosphatase increased
         subjects affected / exposed
    11 / 234 (4.70%)
    15 / 240 (6.25%)
         occurrences all number
    13
    25
    Weight decreased
         subjects affected / exposed
    12 / 234 (5.13%)
    38 / 240 (15.83%)
         occurrences all number
    25
    90
    Weight increased
         subjects affected / exposed
    14 / 234 (5.98%)
    9 / 240 (3.75%)
         occurrences all number
    24
    24
    Nervous system disorders
    Dizziness
         subjects affected / exposed
    30 / 234 (12.82%)
    52 / 240 (21.67%)
         occurrences all number
    46
    85
    Dysgeusia
         subjects affected / exposed
    16 / 234 (6.84%)
    35 / 240 (14.58%)
         occurrences all number
    107
    129
    Headache
         subjects affected / exposed
    46 / 234 (19.66%)
    49 / 240 (20.42%)
         occurrences all number
    98
    129
    Hypoaesthesia
         subjects affected / exposed
    25 / 234 (10.68%)
    18 / 240 (7.50%)
         occurrences all number
    47
    26
    Neuropathy peripheral
         subjects affected / exposed
    60 / 234 (25.64%)
    61 / 240 (25.42%)
         occurrences all number
    141
    113
    Paraesthesia
         subjects affected / exposed
    12 / 234 (5.13%)
    21 / 240 (8.75%)
         occurrences all number
    14
    60
    Peripheral sensory neuropathy
         subjects affected / exposed
    53 / 234 (22.65%)
    48 / 240 (20.00%)
         occurrences all number
    91
    90
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    65 / 234 (27.78%)
    75 / 240 (31.25%)
         occurrences all number
    214
    341
    Leukopenia
         subjects affected / exposed
    74 / 234 (31.62%)
    72 / 240 (30.00%)
         occurrences all number
    332
    382
    Lymphopenia
         subjects affected / exposed
    30 / 234 (12.82%)
    32 / 240 (13.33%)
         occurrences all number
    114
    139
    Neutropenia
         subjects affected / exposed
    79 / 234 (33.76%)
    77 / 240 (32.08%)
         occurrences all number
    307
    289
    Gastrointestinal disorders
    Abdominal distension
         subjects affected / exposed
    4 / 234 (1.71%)
    16 / 240 (6.67%)
         occurrences all number
    7
    36
    Abdominal pain
         subjects affected / exposed
    26 / 234 (11.11%)
    52 / 240 (21.67%)
         occurrences all number
    48
    197
    Abdominal pain upper
         subjects affected / exposed
    18 / 234 (7.69%)
    30 / 240 (12.50%)
         occurrences all number
    24
    267
    Constipation
         subjects affected / exposed
    44 / 234 (18.80%)
    35 / 240 (14.58%)
         occurrences all number
    113
    102
    Diarrhoea
         subjects affected / exposed
    78 / 234 (33.33%)
    222 / 240 (92.50%)
         occurrences all number
    247
    7800
    Dyspepsia
         subjects affected / exposed
    20 / 234 (8.55%)
    31 / 240 (12.92%)
         occurrences all number
    51
    75
    Haemorrhoids
         subjects affected / exposed
    12 / 234 (5.13%)
    4 / 240 (1.67%)
         occurrences all number
    16
    4
    Nausea
         subjects affected / exposed
    70 / 234 (29.91%)
    107 / 240 (44.58%)
         occurrences all number
    191
    415
    Stomatitis
         subjects affected / exposed
    46 / 234 (19.66%)
    59 / 240 (24.58%)
         occurrences all number
    68
    154
    Vomiting
         subjects affected / exposed
    37 / 234 (15.81%)
    87 / 240 (36.25%)
         occurrences all number
    65
    240
    Skin and subcutaneous tissue disorders
    Alopecia
         subjects affected / exposed
    133 / 234 (56.84%)
    126 / 240 (52.50%)
         occurrences all number
    173
    163
    Dry skin
         subjects affected / exposed
    12 / 234 (5.13%)
    15 / 240 (6.25%)
         occurrences all number
    14
    17
    Erythema
         subjects affected / exposed
    16 / 234 (6.84%)
    9 / 240 (3.75%)
         occurrences all number
    19
    19
    Nail disorder
         subjects affected / exposed
    31 / 234 (13.25%)
    33 / 240 (13.75%)
         occurrences all number
    35
    88
    Palmar-plantar erythrodysaesthesia syndrome
         subjects affected / exposed
    7 / 234 (2.99%)
    14 / 240 (5.83%)
         occurrences all number
    12
    35
    Pruritus
         subjects affected / exposed
    22 / 234 (9.40%)
    19 / 240 (7.92%)
         occurrences all number
    27
    24
    Rash
         subjects affected / exposed
    51 / 234 (21.79%)
    72 / 240 (30.00%)
         occurrences all number
    131
    151
    Musculoskeletal and connective tissue disorders
    Arthralgia
         subjects affected / exposed
    45 / 234 (19.23%)
    34 / 240 (14.17%)
         occurrences all number
    74
    69
    Back pain
         subjects affected / exposed
    27 / 234 (11.54%)
    37 / 240 (15.42%)
         occurrences all number
    51
    168
    Bone pain
         subjects affected / exposed
    12 / 234 (5.13%)
    11 / 240 (4.58%)
         occurrences all number
    12
    33
    Muscle spasms
         subjects affected / exposed
    12 / 234 (5.13%)
    17 / 240 (7.08%)
         occurrences all number
    15
    34
    Musculoskeletal chest pain
         subjects affected / exposed
    5 / 234 (2.14%)
    13 / 240 (5.42%)
         occurrences all number
    10
    15
    Musculoskeletal pain
         subjects affected / exposed
    19 / 234 (8.12%)
    13 / 240 (5.42%)
         occurrences all number
    22
    15
    Myalgia
         subjects affected / exposed
    32 / 234 (13.68%)
    31 / 240 (12.92%)
         occurrences all number
    91
    83
    Pain in extremity
         subjects affected / exposed
    25 / 234 (10.68%)
    30 / 240 (12.50%)
         occurrences all number
    41
    54
    Infections and infestations
    Cystitis
         subjects affected / exposed
    12 / 234 (5.13%)
    14 / 240 (5.83%)
         occurrences all number
    40
    25
    Influenza
         subjects affected / exposed
    14 / 234 (5.98%)
    11 / 240 (4.58%)
         occurrences all number
    16
    18
    Nasopharyngitis
         subjects affected / exposed
    34 / 234 (14.53%)
    29 / 240 (12.08%)
         occurrences all number
    103
    113
    Paronychia
         subjects affected / exposed
    9 / 234 (3.85%)
    16 / 240 (6.67%)
         occurrences all number
    9
    32
    Rhinitis
         subjects affected / exposed
    12 / 234 (5.13%)
    2 / 240 (0.83%)
         occurrences all number
    16
    4
    Upper respiratory tract infection
         subjects affected / exposed
    32 / 234 (13.68%)
    27 / 240 (11.25%)
         occurrences all number
    67
    52
    Urinary tract infection
         subjects affected / exposed
    15 / 234 (6.41%)
    17 / 240 (7.08%)
         occurrences all number
    22
    29
    Metabolism and nutrition disorders
    Decreased appetite
         subjects affected / exposed
    41 / 234 (17.52%)
    76 / 240 (31.67%)
         occurrences all number
    153
    236
    Dehydration
         subjects affected / exposed
    3 / 234 (1.28%)
    18 / 240 (7.50%)
         occurrences all number
    3
    21
    Hypercreatininaemia
         subjects affected / exposed
    2 / 234 (0.85%)
    13 / 240 (5.42%)
         occurrences all number
    5
    49
    Hyperglycaemia
         subjects affected / exposed
    16 / 234 (6.84%)
    9 / 240 (3.75%)
         occurrences all number
    26
    16
    Hypocalcaemia
         subjects affected / exposed
    4 / 234 (1.71%)
    19 / 240 (7.92%)
         occurrences all number
    5
    46
    Hypokalaemia
         subjects affected / exposed
    9 / 234 (3.85%)
    23 / 240 (9.58%)
         occurrences all number
    9
    37

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    04 Feb 2010
    The design was changed from a ~350- to ~400-site study. This amendment also included new baseline assessments, changes to inclusion critiera, tumor assessment requirements flow chart, prohibited concomitant treatment, concomitant medication guidelines, ECG schedule, guidelines for evaluating liver function test (LFT) changes and pneumonitis/interstitial lung disease, guidelines for blood collection, new patient monitoring and dose adjustment guidelines, Instructions for laboratory determination, reportable liver function test information. Guidelines for PK sampling for patients with LFT changes and details on determination of neratinib and its metabolite plasma concentrations were also added.
    09 Jun 2011
    The design changed from a 1,200-patient Phase 3 study to a 480-patient Phase 2 study. Analysis of p95 ERBB2 levels with an antibody-based assay was added to biomarkers evaluation. Guidelines for diarrhea management and dose adjustments for diarrhea were revised. Use of patient diaries and distribution of patient diarrhea management cards were made mandatory for all patients enrolled in the neratinib arm. Primary prophylactic use of antidiarrheal medication was mandated. The requirement to collect health outcomes questionnaires was discontinued. Adverse event and SAE reporting procedures were revised to reflect process changes at the Sponsor. Other changes and clarifications were made relative to guidelines of LVEF calculations and selection of lymph node as target vs non-target lesions at screening.
    22 Mar 2012
    The Sponsor was changed to Puma. Updates were made to biomarker sample collection. Overall survival was removed from the secondary endpoints. As a result, the study no longer included a long-term follow-up for survival period. Other updates included the frequency of tumor assessment, discontinuation of PK sample collection, and exapansion of the scenario for possible use of locally supplied trastuzumab and paclitaxel.
    01 Jun 2016
    Treatment Extension Period was added in order to provide study subjects who continue to derive benefit from investigational product (IP) the opportunity to continue to receive study drug with a reduced number of protocol required assessments. Additional changes included tumor assessments performed at the investigator’s discretion; required safety procedures for patients receiving neratinib were limited to reporting of all SAEs and non-serious adverse events leading to drug discontinuation or withdrawal from the trial; adverse event collection for patients who were not receiving neratinib was discontinued.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 00:01:58 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA